


# Novel FolR $\alpha$ -targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

June 3 2023

---



Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithelium (right) and mucinous epithelium that pseudo-stratifies (left - diagnostic of a LMP tumour). Epithelium in a frond-like architecture is seen at the top of image. Credit: Nephron /Wikipedia. CC BY-SA 3.0

Updated dose expansion data of the phase I STRO-002-GM1 study have

been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, U.S..

This global study was designed to evaluate the efficacy and safety of the novel FolR $\alpha$ -targeting antibody drug conjugate (ADC) luveltamab tazevibulin (STRO-002—luvelta) in [patients](#) with recurrent epithelial ovarian cancer with identified expression levels of folate receptor alpha (FolR $\alpha$ ) higher than 25%. This ADC induces cytotoxic and immunologic cell death, and using site-specific conjugation technology and is designed to target a broad range of FolR $\alpha$ -expressing ovarian tumors.

"Folate receptor alpha is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies. Its overexpression in [solid tumors](#) promotes cancer cell proliferation and persists in metastatic or recurrent disease after therapy. This driver of cancer cell proliferation therefore represents a highly relevant target for the development of novel treatment strategies in ovarian and endometrial cancers," said Ana Oaknin, Medical Oncologist at the Vall d'Hebron University Hospital (HUVH), and first author of this present study.

STRO-002-GM1 enrolled 44 patients with advanced ovarian cancer and disease recurrence as a result of platinum chemotherapy resistance after 1-3 prior lines of treatment or platinum sensitive disease after 2-3 previous lines of platinum chemotherapy. FolR $\alpha$  expression was not required for study entry but was analyzed retrospectively in archival tissue to evaluate if the overexpression of this protein could potentially guide patient selection.

Patients were randomized 1:1 to receive luveltamab at 4.3 mg/kg or 5.2 mg/kg (23 patients and 21 patients, respectively). 33 of the 44 patients enrolled in this study presented with FolR $\alpha$  expression levels higher than

25%. The dose expansion data show significant clinical benefit in those patients selected for presenting FolR $\alpha$  expression >25%, with an overall response rate of 37.5%. The investigators observed a 44% response rate in those patients who received treatment with the higher 5.2 mg/kg dose.

The most common adverse events included neutropenia, arthralgia and anemia that were managed with standard medical treatment and dose reductions. Neutropenia had a [higher incidence](#) at 5.2 mg/kg than 4.3 mg/kg. While treatment adverse events led to dose reduction in 76% of patients treated with the 5.2 mg/kg dose, treatment was only suspended in one patient.

"These dose expansion data confirm the encouraging activity of luveltamab tazevibulin at starting doses ranging from 4.3 to 5.2 mg/kg in patients with recurrent, platinum resistant ovarian cancer with FolR $\alpha$  expression levels of more than 25%, and support further clinical evaluation. Led by VHIO investigators in Europe, a global phase II/III study is already planned to evaluate this novel ADC in this patient population," concluded Ana Oaknin.

**More information:** Conference: [conferences.asco.org/am/attend](https://conferences.asco.org/am/attend)

Provided by Vall d'Hebron Institute of Oncology

Citation: Novel FolR $\alpha$ -targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer (2023, June 3) retrieved 19 April 2024 from <https://medicalxpress.com/news/2023-06-folr-targeting-antibody-drug-conjugate-recurrent.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--